Clinical Trials Logo

Clinical Trial Summary

A small-scale pilot randomized controlled trial conducted by the investigators demonstrated some preliminary evidence that inspiratory muscle training (IMT) could be a promising self-management method for alleviating breathlessness. Hence, the aim of this study is to assess the effectiveness of IMT in patients with thoracic malignancies on dyspnea.


Clinical Trial Description

The hypothesis of this study is that inspiratory muscle training (IMT) for a three-month treatment will improve dyspnea in lung cancer patients with stable disease experiencing breathlessness. Plan of Investigation Subjects The sample will be a heterogeneous group of outpatients cared for in a large university medical center in China (Southwest Medical University Hospital). Methods The trial will be a two-arm, non-blinded, randomized controlled study. Patients will be randomly assigned through a computer program to IMT or a control group by an independent statistician. The IMT group will receive standard care and additionally the IMT intervention. The control group will receive standard treatment. Study Design Intervention: A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics. When patients inhale through the IMT device, the valve blocks air flow until the patient generates sufficient inspiratory pressure to overcome the resistance provided by the spring-loaded valve. The patient must generate the inspiratory pressure, in order for the valve to open and allow inhalation of air. The IMT protocol will have five sessions weekly for 12 weeks for 30 mins/day, divided over two sessions. Procedures Participants will be recruited at the outpatients' clinic of Southwest Medical University Hospital or referred to the research team by the clinicians. Patients allocated to the experimental arm will have training in the IMT use and the trainer (device) will be adjusted to a level which is comfortable to each patient. In the control arm, patients will be visited for completing the study assessments at the same times as in the experimental arm (months 2 & 3). Sample Size The investigators have used the mBorg score change [primary outcome] in baseline to month three assessment of 0.80 obtained in the pilot study and the established minimally important difference of 1 for the mBorg to calculate sample size requirements, adding a 25% attrition observed in the pilot study. This corresponds to a sample size of 196 subjects. Data Processing and Analysis The statistical software package IBM SPSS version 23.0 will be used. Descriptive statistics will summarize the sample characteristics. Generalized estimating equations (GEE) models will be used to compare differential changes in the outcomes between the two study arms across multiple time points (baseline-month 2 and month 3 assessment). A p-value of <0.05 was considered statistically significance. Intention-to-treat analysis will be carried out. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03834116
Study type Interventional
Source The Hong Kong Polytechnic University
Contact
Status Completed
Phase N/A
Start date November 23, 2019
Completion date September 15, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT05890872 - Aliyaâ„¢ Pulsed Electric Fields (PEF) for Advanced Cancer N/A
Recruiting NCT05974475 - MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer
Recruiting NCT06079970 - Confocal Laser Endomicroscopy VERification N/A
Recruiting NCT04973293 - Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer N/A
Recruiting NCT04778826 - Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy N/A
Suspended NCT04036721 - Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis Phase 4
Completed NCT03352245 - Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer N/A
Completed NCT03824977 - Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery
Terminated NCT02985203 - Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer Phase 2
Recruiting NCT06440616 - Benefit of Spectral Information in Patients Suspected for Lung Cancer N/A
Active, not recruiting NCT05241873 - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT05404022 - Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years N/A
Not yet recruiting NCT05414188 - Beneficial Effect of Pulmonary Rehabilitation in Lung Cancer Patients Receiving Radiation Therapy N/A
Recruiting NCT03525782 - Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC Phase 1/Phase 2
Completed NCT04059887 - Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] Phase 4
Terminated NCT05013554 - Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors Phase 1